Table 1 Baseline characteristics of the study population.
Variable | Early start (N = 191) | Late start (N = 290) | P-value |
|---|---|---|---|
Gender | 0.956 | ||
Male | 141 (73.8) | 216 (74.5) | |
Female | 50 (26.2) | 74 (25.5) | |
Age at intestinal resection, years | 30.4 ± 12.2 | 30.3 ± 11.8 | 0.952 |
Age at biological therapy, years | 30.7 ± 12.1 | 33.5 ± 12.0 | 0.015 |
Duration between intestinal resection and biological therapy, months | 4.8 ± 3.8 | 39.6 ± 23.0 | < 0.001 |
History of perianal surgery | 9 (4.7) | 28 (9.7) | 0.069 |
Biological therapy after intestinal resection | 0.727 | ||
Infliximab | 53 (27.8) | 86 (29.7) | |
Adalimumab | 138 (72.2) | 204 (70.3) | |
Concomitant medication | |||
5-ASA | 182 (95.3) | 279 (96.2) | 0.794 |
Immunomodulators | 184 (96.3) | 283 (97.6) | 0.602 |
Steroid | 183 (95.8) | 277 (95.5) | 0.128 |
Hospital scale | < 0.001 | ||
Tertiary hospitals | 126 (66.0) | 231 (79.7) | |
General/community hospitals | 65 (34.0) | 59 (20.3) | |
Follow-up duration, months | 44.1 ± 26.9 | 72.2 ± 27.0 | < 0.001 |
